Adimab scientists will present three posters in Poster Session C, highlighting advances in T cell-engaging immunotherapies. Topics include novel CD3 binders, high-throughput discovery of anti-tumor TCRs, and generation of format-diverse, co-stimulatory multispecific antibody panels for CD28- and CD3-driven T cell engagement.